Nadine Attal1. 1. Institut National de la Santé de la Recherche Médicale (INSERM) U 789, Assistance Publique Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne, France. nadine.attal@apr.aphp.fr
Abstract
PURPOSE OF REVIEW: Neuropathic pain (NP) is caused by a lesion of the somatosensory system and is characterized by a combination of positive symptoms (ongoing pain, paroxysmal pain, evoked pain) and negative phenomena (sensory deficit in the painful area). Examples of NP include painful diabetic and nondiabetic neuropathies, postherpetic neuralgia, traumatic nerve lesions, radiculopathies, and central pain (eg, spinal cord injury pain, poststroke pain). This review presents the mechanisms and therapeutic options for NP. RECENT FINDINGS: Consensus recommendations for the treatment of NP or of some neuropathic conditions propose using antidepressants, antiepileptics, and topical lidocaine as first-line treatment and using tramadol and other opioids as second- or third-line treatment. Clinical advances in the management of NP include the implementation of comparative studies and combination therapy trials, the study of rarer and often neglected NP conditions, and the identification of responder profiles based on a detailed characterization of symptoms and signs using sensory examination and specific pain questionnaires. SUMMARY: The management of patients with chronic NP is challenging because of the multiplicity of mechanisms involved in NP conditions. Evidence-based recommendations for the pharmacologic treatment of NP have recently been proposed.
PURPOSE OF REVIEW: Neuropathic pain (NP) is caused by a lesion of the somatosensory system and is characterized by a combination of positive symptoms (ongoing pain, paroxysmal pain, evoked pain) and negative phenomena (sensory deficit in the painful area). Examples of NP include painful diabetic and nondiabetic neuropathies, postherpetic neuralgia, traumatic nerve lesions, radiculopathies, and central pain (eg, spinal cord injury pain, poststroke pain). This review presents the mechanisms and therapeutic options for NP. RECENT FINDINGS: Consensus recommendations for the treatment of NP or of some neuropathic conditions propose using antidepressants, antiepileptics, and topical lidocaine as first-line treatment and using tramadol and other opioids as second- or third-line treatment. Clinical advances in the management of NP include the implementation of comparative studies and combination therapy trials, the study of rarer and often neglected NP conditions, and the identification of responder profiles based on a detailed characterization of symptoms and signs using sensory examination and specific pain questionnaires. SUMMARY: The management of patients with chronic NP is challenging because of the multiplicity of mechanisms involved in NP conditions. Evidence-based recommendations for the pharmacologic treatment of NP have recently been proposed.
Authors: Sohail M Mulla; D Norman Buckley; Dwight E Moulin; Rachel Couban; Zain Izhar; Arnav Agarwal; Akbar Panju; Li Wang; Sun Makosso Kallyth; Alparslan Turan; Victor M Montori; Daniel I Sessler; Lehana Thabane; Gordon H Guyatt; Jason W Busse Journal: BMJ Open Date: 2014-11-20 Impact factor: 2.692
Authors: Anat Galor; Leslie Small; William Feuer; Roy C Levitt; Konstantinos D Sarantopoulos; Gil Yosipovitch Journal: Trans Am Ophthalmol Soc Date: 2018-01-17